Syndax Pharmaceuticals

Yahoo Finance • 7 days ago

Syndax’s Revumenib Added to NCCN AML Guidelines Ahead of October 25 FDA Decision

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the best stocks to buy under $20. On September 19, Syndax Pharmaceuticals announced a major milestone: the National Comprehensive Cancer Network/NCCN updated its Clinical Practice Guideli... Full story

Yahoo Finance • 8 days ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on October 1, 2025 the Company granted inducement... Full story

Yahoo Finance • 23 days ago

Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the National Comprehensive Cancer Network® (NCCN... Full story

Yahoo Finance • 2 months ago

Syndax Announces Participation in September Investor Conferences

NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as w... Full story

Yahoo Finance • 2 months ago

Citi ups Syndax target, opens ‘upside catalyst watch’

Citi analyst Yigal Nochomovitz raised the firm’s price target on Syndax (SNDX) to $51 from $46 and keeps a Buy rating on the shares. The firm also added a positive “upside catalyst watch” on Syndax ahead of the PDUFA deadline in relapsed o... Full story

Yahoo Finance • 2 months ago

Stocks making the biggest moves midday: Pfizer, Palantir, Coinbase, Staar Surgical and more

Check out some of the companies making the biggest moves midday: Staar Surgical — The implantable eye lens maker ripped 45% higher after agreeing to be bought by Alcon for $28 per share in cash, valuing Staar at about $1.5 billion. The dea... Full story

Yahoo Finance • 2 months ago

Stocks making the biggest premarket moves: Pfizer, Eaton, Palantir, Yum and more

Check out the companies making the biggest moves in premarket trading: Palantir Technologies — The defense technology stock jumped 6.8% after quarterly revenue exceeded $1 billion for the first time and it raised full-year guidance. Palant... Full story

Yahoo Finance • 2 months ago

Earnings call transcript: Syndax Pharmaceuticals Q2 2025 beats forecasts, stock rises

Syndax Pharmaceuticals reported its second-quarter 2025 earnings, posting a narrower-than-expected loss per share and exceeding revenue forecasts. The earnings per share (EPS) came in at -$0.83, surpassing the forecast of -$1.01, marking a... Full story

Yahoo Finance • 2 months ago

Syndax Pharmaceuticals earnings beat by $0.18, revenue topped estimates

Investing.com - Syndax Pharmaceuticals (NASDAQ: SNDX) reported second quarter EPS of $-0.83, $0.18 better than the analyst estimate of $-1.01. Revenue for the quarter came in at $37.96M versus the consensus estimate of $27.13M. Syndax P... Full story

Yahoo Finance • 2 months ago

Stocks making the biggest moves after hours: Palantir, Hims & Hers Health, Vertex Pharmaceuticals and more

Check out the companies making headlines in extended trading. Palantir — The defense technology stock advanced 4% after second-quarter earnings exceeded Wall Street's expectations. Palantir said it reported adjusted earnings of 16 cents pe... Full story

Yahoo Finance • 2 months ago

Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update

– $28.6 million of Revuforj® (revumenib) net revenue, representing 43% growth over 1Q25 – – $36.2 million of Niktimvo™ (axatilimab-csfr) net revenue reported by Incyte in first full quarter of launch; $9.4 million in collaboration revenue... Full story

Yahoo Finance • 2 months ago

CCS Dividend Yield Pushes Above 2%

Looking at the universe of stocks we cover at Dividend Channel, in trading on Monday, shares of Century Communities Inc (Symbol: CCS) were yielding above the 2% mark based on its quarterly dividend (annualized to $1.16), with the stock cha... Full story

Yahoo Finance • 2 months ago

Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its second quarter 2025 financial... Full story

Yahoo Finance • 4 months ago

Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia

– PDUFA action date set for October 25, 2025 – – sNDA being reviewed under FDA’s RTOR program – – Revumenib has the potential to become the first and only menin inhibitor approved in both R/R mNPM1 AML and R/R KMT2Ar acute leukemia – NE... Full story

Yahoo Finance • 4 months ago

Syndax Pharmaceuticals' SWOT analysis: revuforj launch boosts aml treatment stock

Syndax Pharmaceuticals , Inc. (NASDAQ:SNDX), a biotechnology company with a market capitalization of $860 million focused on developing cancer treatments, has recently made significant strides in the acute myeloid leukemia (AML) market wit... Full story

Yahoo Finance • 4 months ago

Kura Oncology's SWOT analysis: ziftomenib's potential reshapes AML treatment stock outlook

Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company with a market capitalization of $564 million, is making significant strides in the development of precision medicines for cancer treatment. According to Investin... Full story

Yahoo Finance • 4 months ago

Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025

– Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients – – Promising clinical activity and deep responses observed with 67% (29/43) CR rate, 88% (38/43)... Full story

Yahoo Finance • 4 months ago

Syndax Announces Participation in June Investor Conferences

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syn... Full story

Yahoo Finance • 5 months ago

Syndax Reports First Quarter 2025 Financial Results and Provides Business Update

– $20.0 million in Revuforj® (revumenib) net revenue in first full quarter of launch – – $13.6 million in Niktimvo™ (axatilimab-csfr) net revenue (reported by Incyte) in first partial quarter of launch – – Submitted sNDA for revumenib in... Full story

Yahoo Finance • 7 months ago

Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

– $7.7 million in Revuforj® (revumenib) net product revenue in initial five weeks of launch – – Launched Niktimvo™ (axatilimab-csfr) in the U.S. in late January, in partnership with Incyte – – sNDA filing for revumenib in R/R mNPM1 AML e... Full story